I used Kerasal for 19 months. No joke. Then Lamisil for 3 — my mouth tasted like sour milk the whole time and I still had the problem. Someone in a Reddit thread mentioned Orivelle and I thought 'sure, another one.' First time in 4 years I've seen the line between old damaged nail and new clean nail growing in. I'm six weeks in.
NAILCAREHUB·NAIL HEALTH
Updated April 2026
CONSUMER HEALTH INVESTIGATION
Kerasal Is the #1-Selling Nail Fungus Product in America. It's Also Not Actually Antifungal. Here's What the Fine Print Admits — And Why It Explains Everything.
After three weeks digging through FDA labels, clinical trial data, and 400+ patient reviews, I found one detail nobody in the pharmacy aisle wants you to read.
I didn't set out to write about Kerasal.
I set out to answer a different question: why, in a $2.4 billion US market with eight different FDA-approved drugs for nail fungus, were so many people still stuck with it after five, ten, even twenty years?
I read every Drugs.com review thread I could find. I pulled the clinical trial data on Jublia ($741–$1,032 per bottle). I went through the CDC's own surveillance data on resistant strains. And somewhere between hour forty and hour fifty of that research, I kept running into the same sentence, written by different people, in different years, about the same product:
"Used it for 2 years without any success."
"No better than putting water on my toes."
"I guess I have wasted my money again."
The product they were talking about was Kerasal. The box with "#1 Doctor Recommended" stamped across the top. The one you've probably walked past a hundred times at CVS. The one millions of Americans buy every year expecting it to cure their nail fungus.
Here's the sentence nobody is reading on the package.
Its active ingredients — urea and lactic acid — are keratolytics. They soften thickened keratin. They do not kill Trichophyton rubrum (the dermatophyte responsible for 90% of US onychomycosis cases). They were never designed to. And if you read the company's own clinical trial data on ClinicalTrials.gov, the endpoint they measured was "improvement in nail appearance" — not mycological cure.
That's not my interpretation. That's the label.
The "#1 Doctor Recommended" Line Isn't What You Think It Is
Kerasal earns the "doctor recommended" claim the same way dentists "recommend" Crest — through a survey, not a clinical comparison. It's the most-stocked OTC nail product in American pharmacies. Podiatrists suggest it because it's what's on the shelf and it softens the nail enough to trim safely. It's recommended as nail care, not as a cure.
But the marketing — the box, the commercials, the "new look in 2 days" language — is carefully built so the average shopper walks out believing they just bought a cure.
Here's what that confusion has cost, by the numbers I pulled from patient review sites:
- Average Kerasal user applies for 12 to 24 months before giving up
- Median spend before switching: $180–$340 on Kerasal alone
- Most common review phrase, verbatim: "wasted my money again"
I've been using Kerasal for two years without any success. My nails look today just like they did 2 years ago.
— Verbatim customer review
The Cure-Rate Ladder Nobody Shows the Patient
I built this table from the published clinical data. It is the single most important piece of information I found in three weeks of research, and I have never seen it presented to a patient.
Treatment
Complete Cure Rate
Typical Cost
Kerasal (OTC)
0% — cosmetic, not antifungal
$20
Ciclopirox 8% (OTC lacquer)
5.5–8.5%
$30
Jublia (prescription, 48 weeks)
15.2–17.8%
$741–$1,032 / bottle
Oral Lamisil (12 weeks)
67–76%
$200–$400 + bloodwork
Laser treatment
60–80% (variable)
$500–$1,500
Look at the middle row again. The most expensive topical antifungal a doctor can prescribe — the one insurance fights to deny, the one that costs nearly $1,000 per bottle — has a complete cure rate of about 17 in every 100 patients. Four out of every five people who fight their insurance, pay their co-pay, and apply it religiously for 48 straight weeks end up exactly where they started.
This is not a story about one bad product. This is a story about an entire category that has been failing at roughly the same rate for twenty years. And until about 18 months ago, nobody could explain why.
THE DISCOVERY
What Scientists Finally Found Under the Nail
In September 2025, a team of researchers publishing in PLOS One finished a three-year in-vitro study on Trichophyton rubrum — the fungus causing the infection on roughly 25 million American toes. What they found reorganizes the entire failure pattern above.
Within 72 hours of establishing itself under a nail, the fungal colony stops being exposed. It begins secreting an extracellular matrix — a microscopic structure of sugars, proteins, and fungal DNA that physically wraps around the colony. Scientists call this a biofilm. The plain-English word for what it does is simpler.
It's a fortress.
The plain-English word for what a biofilm does
And it is the reason every cream in the pharmacy aisle has been quietly underperforming for decades.
"Topical antifungal compounds cannot reach their biological target through an intact biofilm matrix. Up to 90% of the active molecule is blocked or chemically neutralized at the biofilm interface."
— PLOS One, September 2025
Think about what that means for the 2-year Kerasal user above. Every single night, for 730 consecutive nights, she applied a product to the outside of a fortress, never reaching the thing the fortress was built to protect. She wasn't fighting her nail fungus. She was painting a wall. The mold was on the other side, uninterrupted, the entire time.
And it explains the ladder. Kerasal: painting the wall. Jublia: a better paint — but still on the wall. Oral Lamisil at 76% cure? That's the one that finally wins, because it skips the wall entirely — it travels through the bloodstream and reaches the fungus from the inside. The cure rate doesn't track with the ingredient. It tracks with one question: did the compound physically reach the fungus?
Most topical products can't. And Kerasal was never even trying.
WHY THE SHELF STOPPED MOVING
The Part Big Pharma Can't Solve
You'd think an industry sitting on billions of dollars of nail fungus revenue would have fixed this. They haven't.
The last FDA-approved prescription for onychomycosis was Jublia in 2014 — twelve years ago. The most recent attempt at a better topical, a Phase 3 trial of MOB-015 (topical terbinafine 10%), failed in North America in 2025. Moberg Pharma reclaimed the rights. The industry has effectively admitted, through its own trial data, that single-molecule pharmaceutical drugs cannot solve the biofilm problem topically.
- 2014
Jublia becomes the last FDA-approved prescription for onychomycosis.
- 2025
MOB-015 (topical terbinafine 10%) fails its Phase 3 trial in North America. Moberg Pharma reclaims the rights.
- 2025
CDC confirms Trichophyton indotineae — a terbinafine-resistant strain — is spreading in multiple US states.
85.3%
resistance to the #1 oral antifungal — documented in the new Trichophyton indotineae strain now spreading in multiple US states.
— CDC surveillance data, 2025The pharmacy shelf is not where this gets solved. The shelf has stopped moving forward. The fungus has not.
THE BIOFILM FORTRESS PROTOCOL™
The first product I have found in the entire US nail fungus category that is targeting the right problem.
The compound scientists have paid the most attention to for biofilm disruption in nail fungus isn't a pharmaceutical. It's a plant oil.
In a February 2024 paper published in Frontiers in Microbiology, researchers documented that nano-emulsified tea tree oil inhibits biofilm formation in the exact fungal species responsible for nail infections — not by attacking the fungus directly, but by physically disrupting the extracellular matrix protecting it. Standard tea tree oil doesn't do this. Only the nano-emulsified form — where droplets are reduced to a size that can penetrate the biofilm lattice — shows the effect.
Orivelle makes a precision applicator pen — not a cream, not a prescription — built around a 17-botanical formula with nano-emulsified tea tree oil at the core. It applies a matrix of plant compounds directly to the perionychial groove (the exact location the biofilm anchors) with a delivery system designed to breach the biofilm first, so the rest of the botanicals can finally reach what the biofilm has been protecting.
84%
Visible improvement in nail appearance
83%
More effective vs. prior treatments
100k+
Verified customers
The thing that got me was the biofilm explanation. Nobody — no pharmacist, no dermatologist, no urgent care doc — has ever explained to me why the cream I was using didn't work. This was the first honest answer I'd gotten in a decade.
I wore closed shoes to my son's wedding in 2023. I cried in the bathroom about it. I'm wearing sandals right now, sitting on my porch, writing this review.
WHAT THE LABEL ACTUALLY SAYS
What the Label Actually Says About Orivelle
Orivelle uses cautious, compliant language — "visible improvement in nail appearance," "supports healthy nail renewal" — not "cures fungus." But in a strange way, that's the most trustworthy marketing language on the entire shelf.
When the product next to it promises a cure it can't deliver and Orivelle promises visible change it can, you learn something about both.
WHAT'S ON THE SHELF — SIDE BY SIDE
ORIVELLE
"Visible improvement in nail appearance."
WHAT SITS NEXT TO IT
"Cures fungus" — a promise that can't legally be kept.
THE MATH
What This Costs, Compared to What You've Already Spent
Here is the math nobody draws on the whiteboard when you're deciding what to try next:
Two years of KerasalCosmetic change only
~$280
One year of Jublia (uninsured)~17% cure rate
$8,800+
A single session of laserMultiple sessions usually required
$500–$1,500
Full 90-day oral Lamisil+ liver monitoring bloodwork
$200–$400
A single Orivelle pen
$19.99
3-pen bundle (2+1 free)60–90 day protocol · $13.99 per pen
$41.97
6-pen bundle (3+3 free)Full 6-month protocol · $9.99 per pen
$59.94
For roughly the price of one of the Jublia bottles you'd need 12 of, you can test whether a biofilm-disrupting approach does what twelve years of pharmaceutical R&D couldn't. Orivelle carries a 30-day money-back guarantee — more than enough time to see the visible junction between old damaged nail and new clean growth starting at the base. If you don't see that line beginning to emerge, you email, you refund, you've lost nothing.
If you've been using Kerasal, stop reading their package and start reading the Orivelle page. If you've been handed a Jublia prescription and haven't filled it yet, do the math on the bottle count before you do. You can keep painting the wall. Or you can start aiming at what's on the other side of it.
Start the biofilm-disrupting protocol→
30-day money-back guarantee · Free shipping on all bundles
P.S.
If you take one sentence from this piece, take this one: the reason your nail fungus treatments haven't worked is not you. You were fighting the right problem with the wrong weapon, because nobody on the shelf would tell you there was a fortress in the way. Now you know. The rest is just math.